Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Physical Activity & Diabetes: Q&A with Dr. Sheri Colberg, PhD.
Part 1 in a 2-part series
57th EASD: Sotagliflozin for Type 2 Diabetes
Calorie Restriction vs. Bariatric Surgery for T2D Remission
Letter from the Editor
When we talked about a single medication that treated multiple defects of diabetes, we used to be referring to 1 pill containing 2 different medications. Good examples of this were Glucovance, which combined glyburide and metformin, or ActoplusMet, which combined pioglitazone and metformin. There were a lot of possible combo products tried, but their use was always tempered by the ability of the fixed dose combinations to accommodate a large group of patients.
This has changed over the years as we have discovered new classes of drugs. This week, our interns look at two of these dual action drugs. Ding Nguyen, PharmD Candidate, University of South Florida, has a feature about sotagliflozin, the first-in-class dual SGLT-1/2 inhibitor, and the use in type 1 and 2 diabetes; and Trina Maglalang RPh, PharmD Candidate 2022 University of Colorado, brings us an update on tirzepatide, the new GLP1-GIP agonist.
Based on the uptake of the SGLT-1’s and GLP-1 in practice today, it makes sense that these new drugs are poised to be blockbusters as soon as they are approved.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES — Diabetes News and Research
I recently gave a webinar for the American College of Sports Medicine (and Technogym) that reached almost 1,200 participants in real time. You can watch the webinar, titled “The Role of Physical Activity in Type 2 Diabetes Management and Prevention,” posted on Youtube.
While it does not yet have FDA approval, researchers find novel dual SGLT-1/2 inhibitor, sotagliflozin, is efficacious and safe for patients with type 2 diabetes.
A low-calorie diet was a safe and effective treatment for individuals with newly diagnosed T2D and obesity.
Tirzepatide’s dual-action may significantly impact a person’s weight management and blood glucose compared to GLP-1 receptor agonists like semaglutide.
Recent trials are showing that gastrointestinal surgery may be the new cure for type 2 diabetes, but few patients have access to it.
Study shows that breastfeeding can provide diabetes inhibiting effects for over three years.
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:
Kornelia Ilias, Creighton University | School of Pharmacy and Health Professions Doctor of Pharmacy Candidate Class of 2022
Oluwatayo Ishola, PharmD. Candidate, South College, School of Pharmacy
Sameen Khan, Pharm.D. Candidate, USF College of Pharmacy
Trina Maglalang RPh, 2022 PharmD Candidate, University of Colorado
Ding Nguyen, PharmD Candidate, University of South Florida Taneja College of Pharmacy
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com